Role of CD147 in the development and diagnosis of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the third leading cause of cancer-related deaths worldwide. HCC is characterized by insidious onset, and most patients are diagnosed at an advanced stage with a poor prognosis. Identification of biomarkers for HCC onset and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1149931
Main Authors Huang, Defa, Rao, Dingyu, Jin, Qing, Lai, Mi, Zhang, Jiali, Lai, Zhonghong, Shen, Haibin, Zhong, Tianyu
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.04.2023
Subjects
angiogenesis
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - pathology
CD147
Cell Line, Tumor
diagnosis
hepatocellular carcinoma
Humans
Immunology
Liver Neoplasms - diagnosis
Liver Neoplasms - pathology
metastasis
diagnosis
CD147
metastasis
angiogenesis
hepatocellular carcinoma
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the third leading cause of cancer-related deaths worldwide. HCC is characterized by insidious onset, and most patients are diagnosed at an advanced stage with a poor prognosis. Identification of biomarkers for HCC onset and progression is imperative to development of effective diagnostic and therapeutic strategies. CD147 is a glycoprotein that is involved in tumor cell invasion, metastasis and angiogenesis through multiple mechanisms. In this review, we describe the molecular structure of CD147 and its role in regulating HCC invasion, metastasis and angiogenesis. We highlight its potential as a diagnostic and therapeutic target for HCC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Xiangliang Yuan, University of Texas MD Anderson Cancer Center, United States
Reviewed by: Manoj Kumar Kashyap, Amity University Gurgaon, India; Stefan Lohse, Saarland University, Germany
These authors have contributed equally to this work and share first authorship
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1149931